Microba Life Sciences reported a 99% year-on-year surge in core testing revenue for Q3 FY26, propelled by strong test volume growth and new clinic contracts in Australia and the UK. The company is advancing a major product release and negotiating a significant corporate transaction to bolster its financial position.
- Core testing revenue up 99% year-on-year
- Annualised test volume run rate exceeds 23,000
- 27 new clinic accounts signed since November 2025
- UK test sales up 232% year-on-year
- Major new diagnostic product planned for Q1 FY27
Core Testing Revenue Surges on Clinic Contracts and UK Growth
Microba Life Sciences Limited (ASX:MAP) posted a near doubling of its core testing revenue in Q3 FY26, reaching $2.1 million; up 99% on the prior corresponding period. This leap was driven by a 58% increase in core test volumes, pushing the annualised run rate above 23,000 tests. Notably, the company has signed 27 new enterprise-style clinic accounts in Australia since November 2025, which have already contributed over 2,800 test sales and represent a potential ordering volume exceeding 19,500 tests annually. This shift towards clinic contracts is central to Microba's strategy to accelerate growth and improve sales efficiency.
In parallel, the UK market demonstrated remarkable momentum, with Microbiome Explorer test sales soaring 232% year-on-year to 816 units in the quarter. The UK adoption curve is tracking ahead of Australia's equivalent post-launch period, benefiting from Microba's acquisition of Invivo Healthcare and the established customer base it brought. This geographic expansion underpins the company's confidence in replicating its Australian success overseas.
Product Innovation and Clinical Validation Bolster Market Position
Microba is preparing to launch a major new diagnostic product in early Q1 FY27, which promises to extend its serviceable addressable market by targeting medical doctors, a significant segment beyond current healthcare practitioners. This product, powered by Microba's proprietary Clinical Logic Engine, is already in beta testing with 25 practitioners across Australia and the UK, receiving positive clinical feedback.
Alongside product innovation, Microba has published a validation paper for its MetaPanel gastrointestinal pathogen test, reporting >99% median specificity and 91% median sensitivity. This clinical evidence is expected to support broader adoption through its partnership with Sonic Healthcare, reinforcing Microba's scientific leadership in microbiome diagnostics.
Therapeutic Partnerships Gain Traction Amid Sector Momentum
The therapeutics arm of Microba is intensifying partnering activities following a series of positive clinical trial readouts in the microbiome therapeutics sector between November 2025 and February 2026. These include successful Phase 1b and Phase 2a trials in inflammatory bowel disease and autoimmune conditions. Microba’s lead asset MAP-315 is nearing Phase 2 readiness, with the sector's clinical validation expected to catalyse further investment and transactions. This aligns with Microba’s strategy to leverage its live biotherapeutic IP assets while pausing further internal R&D investment.
Financial Discipline and Corporate Transaction in Progress
Despite strong revenue growth, total Q3 FY26 revenue was slightly down 2% year-on-year at $3.36 million, reflecting the phase-out of legacy products. The company improved its operating cash outflow by approximately 25% quarter-on-quarter through restructuring and laboratory consolidation, maintaining rigorous cost discipline. Cash on hand stood at $7.28 million at quarter end, supported by a $2 million R&D tax incentive loan facility.
Microba is currently engaged in confidential negotiations for a significant corporate transaction expected to strengthen its financial position. The deal remains incomplete and subject to shareholder approval and other conditions. Any binding agreement will be announced once finalized, marking a pivotal development for the company’s capital strategy.
These results build on Microba’s previous momentum, including its 90% year-on-year growth in core test volumes and 123% rise in core testing revenue reported in Q2 FY26, highlighting a sustained growth trajectory across markets.
Bottom Line?
Microba’s strong Q3 performance and upcoming product launch position it well for scaling clinical adoption, but the outcome of its pending corporate transaction will be critical to sustaining momentum into FY27.
Questions in the middle?
- Will the significant corporate transaction materialize and how will it impact Microba’s capital structure?
- How will the new diagnostic product influence adoption among medical doctors beyond current practitioner segments?
- Can Microba sustain its UK growth momentum and replicate Australian clinic contract success internationally?